BCM
RCUS icon

BluePath Capital Management’s Arcus Biosciences RCUS Stock Holding History

BluePath Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,568
Closed -$28.1K – 276
2023
Q3 		$28.1K Buy
+1,568
New +$31.5K 0.03% 300

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BluePath Capital Management's RCUS Position: Q4 2023 in Review

BluePath Capital Management sold out of Arcus Biosciences (RCUS) in Q4 2023, closing a stake of 1,568 shares — an estimated $28.1K sold.

BluePath Capital Management first reported a position in RCUS in Q3 2023 and held it in 1 quarter. The position peaked at $28.1K in Q3 2023. 185 funds tracked by Wall St. Rank hold RCUS as of Q4 2023.

  • BluePath Capital Management reported no remaining Arcus Biosciences position as of Q4 2023 after selling out during the quarter.
  • BluePath Capital Management sold 1,568 Arcus Biosciences shares in Q4 2023, an estimated $28.1K.
  • BluePath Capital Management first reported a position in Arcus Biosciences in Q3 2023 and held it in 1 quarter.
  • BluePath Capital Management's Arcus Biosciences position peaked at $28.1K in Q3 2023.
  • 185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2023.

Based on BluePath Capital Management's 13F filing for Q4 2023, filed 11 Jan 2024.